Fig. 6

Potential ferroptosis-inducing therapy strategy targeting HSPB1. A. Immunofluorescent (IF) staining of HSPB1 in U-251 MG cells. For full IF staining profiles, view the protein at https://www.proteinatlas.org. B. Volcano plots showing the differences in drug sensitivity between glioma cells with high mRNA expression of HSPB1 versus remaining glioma cells. P-values were calculated by Mann–Whitney U test. C. Illustration showing ipatasertib could inhibit kinases AKT and PRKG1 activity, decreasing HSPB1 phosphorylation, thus promoting cancer cell ferroptosis